DURHAM, North Carolina – February 10, 2015 -- Arcato Laboratories, Inc., an emerging oral health company, announced today that it has been selected as a finalist for the AUTM 2015 Venture Forum Business Plan Competition, to be held later this month in New Orleans, Louisiana.
Arcato’s lead product, a medical device named OraWax™, will target orthodontists and their patients as the first effective treatment for oral discomfort and pain caused by orthodontic appliances (braces). Based on intellectual property exclusively licensed to Arcato, OraWax™ relieves the irritation and discomfort experienced by the approximately two million new patients who receive braces each year in the United States.
“We are excited to have been selected as a finalist in the AUTM Venture Forum competition,” said Christopher S. Meldrum, President of Arcato Laboratories. “Arcato represents an exciting new opportunity, and this is the first step in our journey to launch OraWax™ into a marketplace which is sorely in need of a treatment for orthodontic brace pain.”
Based on the frequency of orthodontist visits for brace patients, Arcato estimates a total addressable market for a brace pain-relief product to be greater than $350 million per year in the United States.
Arcato was formed based on the breakthrough scientific inventions by Dr. Michael Jay, Fred N. Eshelman Distinguished Professor and Chair of the Division of Molecular Pharmaceutics at the University of North Carolina at Chapel Hill. Arcato’s initial funding was received from Golden Pine Ventures.
About Arcato Laboratories, Inc.
Arcato Laboratories’ mission is to become a leading oral health company by commercializing unique, proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). Arcato is also developing future products by expanding on its current proprietary technology platform, as well as aggressively seeking to create or in-license complementary intellectual property. For more information: www.arcatolabs.com.
Contact:
Christopher S. Meldrum
President
Arcato Laboratories, Inc.
(919) 473-9296
Help employers find you! Check out all the jobs and post your resume.
Arcato’s lead product, a medical device named OraWax™, will target orthodontists and their patients as the first effective treatment for oral discomfort and pain caused by orthodontic appliances (braces). Based on intellectual property exclusively licensed to Arcato, OraWax™ relieves the irritation and discomfort experienced by the approximately two million new patients who receive braces each year in the United States.
“We are excited to have been selected as a finalist in the AUTM Venture Forum competition,” said Christopher S. Meldrum, President of Arcato Laboratories. “Arcato represents an exciting new opportunity, and this is the first step in our journey to launch OraWax™ into a marketplace which is sorely in need of a treatment for orthodontic brace pain.”
Based on the frequency of orthodontist visits for brace patients, Arcato estimates a total addressable market for a brace pain-relief product to be greater than $350 million per year in the United States.
Arcato was formed based on the breakthrough scientific inventions by Dr. Michael Jay, Fred N. Eshelman Distinguished Professor and Chair of the Division of Molecular Pharmaceutics at the University of North Carolina at Chapel Hill. Arcato’s initial funding was received from Golden Pine Ventures.
About Arcato Laboratories, Inc.
Arcato Laboratories’ mission is to become a leading oral health company by commercializing unique, proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). Arcato is also developing future products by expanding on its current proprietary technology platform, as well as aggressively seeking to create or in-license complementary intellectual property. For more information: www.arcatolabs.com.
Contact:
Christopher S. Meldrum
President
Arcato Laboratories, Inc.
(919) 473-9296
Help employers find you! Check out all the jobs and post your resume.
